Discovery of transdermal penetration enhancers by high-throughput screening

Nature Biotechnology

Volumn 22, Issue 2, 2004, Pages 192-197

  Karande, Pankaj ^a   Jain, Amit ^a   Mitragotri, Samir ^a  

^a University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG PRODUCTS; HORMONES; SKIN;

SKIN PENETRATION;

BIOTECHNOLOGY;

DODECYL SULFATE SODIUM; GONADORELIN; INULIN; LEUPRORELIN; LOW MOLECULAR WEIGHT HEPARIN; MANNITOL; METHOTREXATE; N LAUROYLSARCOSINE; OLIGONUCLEOTIDE; PENETRATION ENHANCING AGENT; PHENYLPIPERAZINE; PIPERAZINE DERIVATIVE; SARCOSINE; SORBITAN LAURATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; HUMAN; HUMAN CELL; IMPEDANCE; IN VITRO STUDY; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SKIN IRRITATION; SKIN PERMEABILITY; STRATUM CORNEUM; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; DRUG SYNERGISM; FEASIBILITY STUDIES; HUMANS; PHARMACEUTICAL PREPARATIONS; RATS; SKIN; SKIN ABSORPTION; VEHICLES;

ANIMALIA;

EID: 0742288421     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt928     Document Type: Article

References (33)

1. Zaffaroni, A. Overview and evolution of therapeutic systems. Ann. NY Acad. Sci. 618, 405-421 (1991).
2. Bos, J.D. & Meinardi, M.M. The 500 dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. 9, 165-169 (2000).
3. Wertz, P.W. & Downing, D.T. in Transdermal Drug Delivery: Developmental Issues and Research Initiatives (eds. Hadgraft, J. & Guy, R.H.) 1-17 (Marcel Dekker, New York, Basel, Hong Kong, 1989).
4. Guy, R. et al. Iontophoresis: electrorepulsion and electroosmosis. J. Control. Release 64, 129-132 (2000).
5. Mitragotri, S., Blankschtein, D. & Langer, R. Ultrasound-mediated transdermal protein delivery. Science 269, 850-853 (1995).
6. Finnin, B.C. & Morgan, T.M. Transdermal penetration enhancers: applications, limitations and potential. J. Pharm. Sci. 88, 955-958 (1999).
7. Williams, A.C. & Barry, B.W. Skin absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst. 9, 305-353 (1992).
8. French, E., Potton, C. & Walters, K. in Pharmaceutical Skin Penetration Enhancement (eds. Walters, K. & Hadgraft, J.) 113-144 (Marcel Dekker, New York, Basel, Hong Kong, 1993).
9. Kanikkannan, N., Kanimalla, K., Lamba, S.S. & Singh, M. Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. Curr. Med. Chem. 7, 593-608 (2000).
10. Lashmar, U.T., Hadgraft, J. & Thomas, N. Topical application of penetration enhancers to the skin of nude mice - a histopatholgical study. J. Pharm. Pharmacol. 41, 118-122 (1989).
11. Akimoto, T. & Nagase, Y. Novel transdermal drug penetration enhancer: synthesis and enhancing effect of alkyldisiloxane compounds containing glucopyranosyl group. J. Control. Release 88, 243-252 (2003).
12. Takanashi, Y., Higashiyama, K., Komiya, H., Takayama, K. & Nagai, T. Thiomenthol derivatives as novel percutaneous absorption enhancers. Drug Dev. Ind. Pharm. 25, 89-94 (1999).
13. Suhonen, M., Bouwstra, J. & Urtti, A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J. Control. Release 59, 149-161 (1999).
14. Mitragotri, S. Effect of bilayer disruption on transdermal transport of low-molecular weight hydrophobic solutes. Pharm. Res. 18, 1022-1028 (2001).
15. Robinson, M.K. & Perkins, M.A. A strategy for skin irritation testing. Am. J. Contact Dermat. 13, 21-19 (2002).
16. Mitragotri, S. Synergistic effect of enhancers for transdermal drug delivery. Pharm. Res. 17, 1354-1359 (2000).
17. Funke, A.P. et al. Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers and solvents from liquid formulations. Pharm. Res. 19, 661-668 (2002).
18. Bronaugh, R.L. in Percutaneous Absorption: Mechanisms-Methodology-Drug Delivery (eds. Bronaugh, R.L. & Maibach, H.I.) (Marcel Dekker, New York, Basel, Hong Kong, 1989).
19. Karande, P. & Mitragotri, S. High-throughput screening of transdermal formulations. Pharm. Res. 19, 655-660 (2001).
20. Black, G. in Pharmaceutical Skin Penetration Enhancement. (eds. Walters, K. & Hadgraft, J.) 145-174 (Marcel Dekker, New York, Basel, Hong Kong, 1993).
21. Fentem, J.H. & Botham, P.A. ECVAM's activities in validating alternative tests for skin corrosion and irritation. Altern. Lab. Anim. 30, 61-67 (2002).
22. Lanigan, R.S. Final report on the safety assessment of cocoyl sarcosine, lauroyl sarcosine, myristoyl sarcosine, oleoyl sarcosine, stearoyl sarcosine, sodium cocoyl sarcosinate, sodium lauroyl sarcosinate, sodium myristoyl sarcosinate, ammonium cocoyl sarcosinate and ammonium lauroyl sarcosinate. Int. J. Toxicol. 20, 1-14 (2001).
23. Loffler, H. & Happle, R. Profile of irritant patch testing with detergents: sodium lauryl sulfate, sodium laureth sulfate and alkyl polyglucoside. Contact Dermatitis 48, 26-32 (2003).
24. Berardesca, E. et al. Ranking of surfactant skin irritancy in vivo in man using the plastic occlusion stress test (POST). Contact Dermatitis 23, 1-15 (1990).
25. Hall-Manning, J., Holland, H., Basketter, A. & Barratt, D. Skin irritation potential of mixed surfactant systems in a human 4-hour covered patch test. Allergologie, 18, 465 (1995).
26. Fentem, J. et al. A prevalidation study on in vitro tests for acute skin irritation: results and evaluation by the Management Team. Toxicology In Vitro 15, 57-93 (2001).
27. Periti, P., Mazzei, T. & Mini, E. Clinical pharmacokinetics of depot leuprorelin. Clin. Pharmacokinet. 41, 485-504 (2002).
28. Frydman, A. Low-molecular weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 26, 24-38 (1996).
29. Peck, K., Ghanem, A. & Higuchi, W. Hindered diffusion of polar molecules through and effective pore radii estimates of intact and ethanol treated human epidermal membrane. Pharm. Res. 11, 1306-1314 (1994).
30. Tang, H., Mitragotri, S., Blankschtein, D. & Langer, R. Theoretical description of transdermal transport of hydrophilic permeants: application to low-frequency sonophoresis. J. Pharm. Sci. 90, 543-566 (2001).
31. Tezel, A., Sens, A. & Mitragotri, S. A theoretical description of transdermal transport of hydrophilic solutes induced by low-frequency sonophoresis. J. Pharm. Sci. 92, 381-393 (2003).
32. Mitragotri, S. et al. Determination of the threshold energy dose for ultra-sound-induced transdermal drug delivery. J. Control. Release 63, 41-52 (2000).
33. Mitragotri, S. Modeling skin permeability to hydrophilic and hydrophobic solutes based on four permeation pathways. J. Control. Release 86, 69-92 (2003).